425: Matinas BioPharma to Combine with GH Power, Sell LNC Unit

Matinas BioPharma Holdings, Inc. announced a business combination with GH Power Inc. to form a clean energy company, alongside the sale of its LNC platform and MAT2203 to Azurity Pharmaceuticals.

Summary

• Matinas BioPharma Holdings, Inc. (MTNB) has entered into a Business Combination Agreement (BCA) with GH Power Inc. to create a publicly traded clean energy company focused on modular reactors for advanced materials, green hydrogen, and industrial decarbonization.
• The combined entity, expected to be named GH Power International, will be listed on the NYSE American.
• Concurrently, Matinas is selling its subsidiary, Matinas BioPharma Nanotechnologies, Inc., which holds its lipid nano-crystal (LNC) drug delivery technology and lead product candidate MAT2203, to Azurity Pharmaceuticals.
• The business combination is anticipated to close in the fourth quarter of 2026, subject to customary closing conditions, including stockholder approvals.
• Matinas stockholders are expected to own approximately 9% of the combined company on a fully diluted basis, while GH Power equityholders are expected to own approximately 91%.
• The sale of Matinas BioPharma Nanotechnologies to Azurity includes an upfront payment of $4.0 million, up to $17.5 million in potential milestone payments, and mid-single-digit royalties on net sales and licensing proceeds for MAT2203.
• Matinas also completed a Series D financing, raising $575,000 in gross proceeds, and a warrant inducement, raising approximately $2.6 million in gross proceeds from the exercise of existing warrants.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it represents a significant strategic shift and potential for growth in a new sector, but also involves the divestiture of the company's core biopharmaceutical assets and carries execution risks associated with the business combination.

Positives

• Creation of a new, publicly traded clean energy company focused on modular reactors, green hydrogen, and critical materials.
• GH Power's proprietary technology addresses growing demand for behind-the-meter power, onshoring of critical mineral production, and industrial decarbonization.
• The business combination is expected to provide access to public capital markets to accelerate commercialization and project development.
• The sale of the LNC platform and MAT2203 to Azurity provides upfront cash and potential future payments, allowing Matinas to focus on the clean energy sector.
• Matinas stockholders will participate in the growth of the combined clean energy entity.
• The Series D financing and warrant inducement provided immediate capital for working capital and general corporate purposes.

Negatives

• Matinas BioPharma stockholders will have a significantly reduced ownership stake (approximately 9%) in the combined entity.
• The sale of the LNC platform and MAT2203 represents a divestiture of the company's biopharmaceutical assets.
• The business combination is subject to numerous closing conditions, including stockholder approvals and regulatory effectiveness, creating execution risk.
• The company's former biopharmaceutical business will be separated, potentially impacting its historical focus and investor base.
• A former financial advisor is entitled to a $2.0 million cash fee and $2.0 million in Pubco Common Shares upon closing.

Risks

• The risk that the Business Combination or the Stock Sale may not be completed in a timely manner or at all.
• Failure by the parties to satisfy the conditions to the consummation of the Business Combination or the Stock Sale, including the approval of Matinas stockholders.
• The risk that the GH Power financing may not be completed on the anticipated terms or at all, including the risk that gross proceeds of at least $15.0 million may not be raised.
• Failure to realize the anticipated benefits of the Business Combination or the Stock Sale.
• Failure to receive the consideration, milestone payments, royalties or licensing proceeds expected in connection with the Stock Sale.
• The failure of Pubco (GHP International) to obtain or maintain the listing of its securities on the NYSE American after closing.
• Costs related to the Business Combination, the Stock Sale and becoming a public company.
• Changes in business, market, financial, political, and regulatory conditions.
• Risks relating to Pubco's (GHP International's) anticipated operations and business and the assets and business of Matinas BioPharma Nanotechnologies, Inc.
• The outcome of any potential legal proceedings that may be instituted against the Company, GH Power, Pubco, Azurity or others following announcement of the transactions.
• The Board of Directors may make a change in recommendation if a superior offer is received, potentially impacting the business combination.
• Termination of the BCA under specified circumstances could result in a $1.0 million termination fee payable by Matinas or GH Power.

Future Outlook

The combined company, GH Power International, aims to accelerate the commercialization and deployment of GH Power's proprietary modular reactor technology, expand project development, and pursue opportunities in clean energy, green hydrogen, industrial decarbonization, and critical materials markets. The company expects to leverage public capital markets for growth. The sale of Matinas BioPharma Nanotechnologies allows Matinas to focus on its clean energy strategy.

Management Comments

• "This transaction marks a defining milestone for GH Power and reflects years of technology development, engineering and execution," said David White, Chief Executive Officer of GH Power. "Becoming a publicly traded company is expected to strengthen our access to capital, enhance our strategic visibility, and accelerate the commercialization of our proprietary modular reactor technology."
• "We are focused on deploying our technology across industrial applications, expanding our strategic partnerships and entering new markets where demand for critical minerals, behind-the-meter power and green hydrogen continues to grow. We believe this transaction positions GH Power to execute on its commercial pipeline and deliver sustainable long-term value for customers and shareholders."
• "Following a comprehensive review of strategic alternatives, our Board concluded that this transaction represents a compelling strategic opportunity to maximize long-term value for our stockholders," said Jerome D. Jabbour, Chief Executive Officer of Matinas. "We believe this transaction positions our stockholders to participate in an innovative company focused on advanced clean energy, green hydrogen and critical minerals markets that are attracting significant global investment and are expected to experience substantial long-term growth while also unlocking the value of our LNC technology platform and MAT2203 through their sale to Azurity."

Industry Context

StockSavvy.ai notes that this transaction signifies a strategic pivot for Matinas BioPharma from a biopharmaceutical focus to the rapidly growing clean energy and green hydrogen sectors, driven by the business combination with GH Power. The divestiture of its LNC platform and MAT2203 to Azurity Pharmaceuticals allows for a clear separation of business lines and capitalizes on the value of its legacy assets. This move aligns with broader industry trends of companies seeking to capitalize on the energy transition and the increasing demand for sustainable technologies and critical materials.

Comparison to Industry Standards

• The expected ownership split of approximately 91% for GH Power equityholders and 9% for Matinas equityholders post-combination is a common outcome in SPAC mergers or reverse mergers where the operating company (GH Power) is significantly larger or more advanced in its commercialization stage than the publicly traded shell company (Matinas).
• The upfront cash consideration of $4.0 million for the sale of Matinas BioPharma Nanotechnologies, Inc. to Azurity Pharmaceuticals, with potential for up to $17.5 million in milestones and royalties, is within the typical range for the sale of a subsidiary with a lead product candidate and a technology platform, depending on the stage of development and market potential of MAT2203.
• The $15.0 million minimum financing requirement for GH Power as a closing condition is a standard practice to ensure the combined entity has sufficient capital to execute its go-forward strategy, especially for companies in capital-intensive sectors like clean energy and hydrogen.
• The conversion ratio of 0.1 Pubco Common Shares per Matinas common stock is a typical mechanism in reverse mergers to adjust for the relative valuations and capitalizations of the merging entities, often reflecting a significant premium for the operating company.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions the possibility of legal proceedings against the Company, GH Power, Pubco, Azurity, or others following the announcement of the Business Combination, Stock Sale, or other transactions.

Related Party Transactions

• A former financial advisor to the Company is entitled to receive $2.0 million in cash and $2.0 million of Pubco Common Shares upon the closing of the Business Combination.
• Certain directors, officers, and stockholders of Matinas entered into voting agreements to support the Business Combination.
• Certain officers, directors, and shareholders of GH Power entered into voting agreements to support the Business Combination.
• The CEO, Jerome D. Jabbour, has an amended employment agreement that extends the trigger date for a retention bonus to December 31, 2026, and a portion of this bonus is currently payable.

Stakeholder Impact

• Matinas BioPharma Stockholders: Will receive 0.1 Pubco Common Share for each Matinas common stock, resulting in approximately 9% ownership of the combined entity. They will participate in the clean energy business but divest from the biopharmaceutical sector.
• GH Power Equityholders: Expected to own approximately 91% of the combined entity, gaining access to public markets and capital for growth.
• Former Holders of Matinas Series A Preferred Stock: Entitled to an aggregate of 7.5% of amounts received by Matinas from Azurity in connection with the Stock Sale, including upfront payment, milestones, and royalties.
• Employees: Potential impact on employees of Matinas BioPharma Nanotechnologies, as their roles and the business unit will be transferred to Azurity. Employees of Matinas BioPharma (post-divestiture) will focus on the clean energy sector.
• Creditors: The transactions may impact the capital structure and debt obligations of the involved entities, though specific impacts are not detailed.
• Suppliers: Changes in business focus may alter supplier relationships for Matinas BioPharma.

Next Steps

• Prepare and file a registration statement on Form F-4 with the SEC, containing a proxy statement/prospectus.
• Obtain requisite stockholder approvals for the Business Combination, Stock Sale, Matinas PIPE, and Warrant Inducement.
• Complete the financing by GH Power, aiming for at least $15.0 million in gross proceeds.
• Obtain necessary Ontario court approvals for the plan of arrangement.
• Secure listing approval for GH Power International's common shares on the NYSE American.
• Complete the Business Combination with GH Power.
• Complete the Stock Sale of Matinas BioPharma Nanotechnologies to Azurity Pharmaceuticals.
• The Board of Directors of the combined company (GH Power International) will be composed of five individuals, with four designated by GH Power and one by Matinas.
• The CEO and CFO of the combined company are expected to be the individuals serving in those roles at GH Power.

Key Dates

Recommendation

The filing details a significant strategic transformation for Matinas BioPharma, moving from biopharmaceuticals to clean energy via a business combination, while divesting its legacy assets. While this offers potential for growth in a high-demand sector, the reduced ownership stake for existing Matinas shareholders, the execution risks associated with the business combination and financing, and the loss of the biopharmaceutical focus warrant a cautious 'hold' recommendation until the combined entity demonstrates its ability to execute its strategy and achieve profitability in the clean energy market.

Keywords

Business Combination, GH Power, Matinas BioPharma, Clean Energy, Green Hydrogen, Critical Minerals, Industrial Decarbonization, Stock Sale, Azurity Pharmaceuticals, LNC Technology, MAT2203, PIPE Financing, Warrant Exercise, Form 8-K, SEC Filing